AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 271 min read$TRDA

MPM BioVentures 2014, L.P. (EVNIN LUKE, GADICKE ANSBERT) sold $462K of TRDA (indirect holdings)

MPM BioVentures 2014, L.P. sold 62,714 indirectly-held shares of Entrada Therapeutics, Inc. (TRDA) at an average of $7.36 ($7.06–$7.54, $0.46M total) across 3 trades over 2026-08-24 to 2026-08-26. Filed jointly with EVNIN LUKE (10% owner), GADICKE ANSBERT (10% owner), Foley Todd (10% owner), MPM BioVentures 2014 (B), L.P. (10% owner), MPM Asset Management Investors BV2014 LLC (10% owner), MPM BioVentures 2014 LLC (10% owner), MPM BioVentures 2014 GP LLC (10% owner), MPM BIOVENTURES 2018 (B), L.P. (10% owner) and MPM ASSET MANAGEMENT INVESTORS BV2018 LLC (10% owner).

Original reporting
SEC EDGAR · MPM BioVentures 2014, L.P., EVNIN LUKE, GADICKE ANSBERT, Foley Todd, MPM BioVentures 2014 (B), L.P., MPM Asset Management Investors BV2014 LLC, MPM BioVentures 2014 LLC, MPM BioVentures 2014 GP LLC, MPM BIOVENTURES 2018 (B), L.P., MPM ASSET MANAGEMENT INVESTORS BV2018 LLC
Published Aug 27, 2026, 1:28 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 27, 2026, 2:10 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$TRDA
Neutral
medium confidence
Mentioned
$TRDA
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TRDANeutralLow
01

Why it matters

The disclosed sale is modest and unlikely to move the stock significantly.

02

Market read

Routine insider sale with limited trading relevance.

03

What to watch

Potential upcoming clinical data or financing events not disclosed.

Relevance 4/10Novelty 4/10Timing: reported on 2026-08-26 after filing

Background

SEC Form 4 filings provide primary disclosure of insider transactions.

Company-level read

Ticker impact

$TRDANeutralMedium confidence
Context

Form 4 disclosed a $462K open‑market sale of 62,714 shares by insiders of Entrada Therapeutics.

Expected impact

Minor downward pressure, likely within normal volatility range.

Evidence & confidence

Sale amount is small relative to market cap; no 10b5‑1 plan; typical insider diversification.

Market effects

Sector

Limited impact on biotech sector; reflects routine insider activity.

Regional

No regional effect.

Global

Minimal global relevance.

Counterpoint

What could challenge this read

Insider sell could be unrelated to fundamentals; may not affect price.

Key entities

  • Company
    Entrada Therapeutics, Inc.

    Biotech firm (ticker TRDA) subject of insider sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TRDA insider trading history →

Related articles

OCT 14
$TRDAMed

Entrada Therapeutics Advances Duchenne Study To Highest Planned Dose Level

Entrada Therapeutics (TRDA) will test its Duchenne muscular dystrophy therapy, ENTR-601-44, at the highest planned dose (18 mg/kg) in its Phase 1/2 study after a favorable safety review. The study aims to evaluate safety, tolerability, and effectiveness in patients aged 4 to 20. Data from earlier cohorts are expected by the end of 2026 and early 2027.

rttnews.com1 min
OCT 14
$TRDAMedAI 9/10

Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201…

Entrada Therapeutics, Inc. (TRDA) filed an SEC Form 8-K — Other Events. Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45 -- Cohort 1 met the primary objectives of favorable safety and tolerability at the initial dose of 5 m

SEC EDGAR 8-K2 min
OCT 14
$TRDAMedAI 8/10

Entrada reports phase 1/2 trial data for DMD therapy candidate

Entrada Therapeutics (TRDA) reported positive phase 1/2 trial data for ENTR-601-45 in Duchenne muscular dystrophy patients. The study met safety and tolerability goals, with treated patients showing increased dystrophin and exon skipping. Adverse events were mild. Cohort 2 data is expected in 2027. The company plans higher doses in subsequent cohorts.

investing.com2 min
OCT 14
$TRDAMedAI 8/10

Entrada receives clearance to test highest dose in DMD trial

Entrada Therapeutics (TRDA) advanced to the highest dose in its DMD trial after positive safety and pharmacokinetic data. The Phase 1/2 study, ELEVATE-44-201, is evaluating ENTR-601-44 for Duchenne muscular dystrophy. The company expects data from Cohort 1 by year-end 2026 and Cohort 2 in Q1 2027. ENTR-601-44 targets 8% of the global DMD patient population and received FDA Rare Pediatric Disease Designation in December 2025.

investing.com2 min